Cardiovascular diseases are the leading cause of death worldwide, claiming over 20 million lives each year. In recognition of #WorldHeartDay, we emphasize the significance of prioritizing #cardiovascular health across all countries by integrating it into national health plans, supporting World Heart Federation's global call to action. This year's theme "𝗨𝘀𝗲 𝗛𝗲𝗮𝗿𝘁 𝗳𝗼𝗿 𝗔𝗰𝘁𝗶𝗼𝗻" delivers a powerful message to leaders worldwide in paving the way towards chances for more effective treatments and earlier diagnoses. Clinical research plays a crucial role in this mission, as it establishes the foundation for both understanding and recognizing the importance of routine medical check-ups for everyone. Conditions such as high blood pressure or diabetes can increase the risk of cardiovascular diseases, so preventive measures are always the first step in taking action. Join us in raising awareness about heart diseases and making a difference! #HeartYes #UseHeart #ClinicalTrials
Alcedis - a HUMA company
Forschungsdienstleistungen
Full-Service CRO | Alcedis ist ein weltweit agierender Marktführer für digitale klinische Studien
Info
Mit über 30 Jahren Erfahrung kombiniert Alcedis medizinische Expertise mit bahnbrechenden Technologien und leistet so Pionierarbeit in der datengetriebenen klinischen Forschung. Unser modulbasiertes Servicekonzept und flexibles Datenerfassungssystem passt sich nahtlos jeder Projektstruktur an und begleitet Ihren gesamten Forschungsprozess - von Phase I bis zur Arzneimittelzulassung und über den Marktzugang hinaus.
- Website
-
https://www.alcedis.de/?utm_source=social&utm_medium=linkedin&utm_campaign=website-button_03-24
Externer Link zu Alcedis - a HUMA company
- Branche
- Forschungsdienstleistungen
- Größe
- 51–200 Beschäftigte
- Hauptsitz
- Gießen
- Art
- Kapitalgesellschaft (AG, GmbH, UG etc.)
- Gegründet
- 1992
- Spezialgebiete
- Clinical Research, IT-Solutions, Digital Health, Clinical Operation, Regulatory , Monitoring, Medical Writing, Data Management , Pharmacovigilance, Biometrics, Sponsor Oversight, eCRF / EDC, ePRO / eCOA, eCONSENT , EHR2EDC, Integrations, Telemedicine, AI Solutions und Analytics
Orte
-
Primär
Winchesterstr. 3
Gießen, 35394, DE
-
Notkestraße 7
Hamburg, 22607, DE
Beschäftigte von Alcedis - a HUMA company
-
Dr. Marc Hetzel
Head of Business Development at Alcedis - a HUMA company
-
Rupert Skinner
Design lead | Digital product and brand designer | Strategy facilitator | Digital health | Tech for good
-
Franziska Ehlicke
Clinical Site Manager
-
Marija Halbach
Senior Clinical Research Project Manager bei Alcedis GmbH
Updates
-
We are excited to take part in the 𝟮𝗻𝗱 𝗔𝗻𝗻𝘂𝗮𝗹 𝗥𝗲𝗮𝗹-𝗪𝗼𝗿𝗹𝗱 𝗘𝘃𝗶𝗱𝗲𝗻𝗰𝗲 𝗮𝗻𝗱 𝗠𝗮𝗿𝗸𝗲𝘁 𝗔𝗰𝗰𝗲𝘀𝘀 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 in the beautiful city of #Freiburg this year. Meet us on 𝗢𝗰𝘁𝗼𝗯𝗲𝗿 𝟭𝟰-𝟭𝟱, 𝟮𝟬𝟮𝟰, to explore the latest developments in European regulatory frameworks surrounding Real-World Evidence and their defining impact on post-market access strategies. As we look to the future of clinical trials, we are placing a special focus on the utilization of Real-World Evidence data, particularly in relation to data capture, patient recruitment, retrospective analysis, and assessing trial feasibility for prospective post-market access studies. We look forward to engaging with global experts through interactive panel discussions, explore effective collaboration methods, and develop new perspectives on patient outcomes to create a lasting impact on the future of clinical research and the work of CROs. Hanno Härtlein Dr. Benedikt Linder Dr. Hendrik Melior MarketsandMarkets™ #marketsandmarkets #Conference #ClinicalTrials
-
Ready and excited for tomorrow! Don't forget to reserve your spot at our upcoming #webinar! 💡See how #RWE shapes the adoption of new treatments 💡Get insights and learnings from the #InspeCKD study, which analyzed half a million anonymized patient records in Germany 💡Learn about the technical integration of RWE in clinical trials There will also be a Q&A session afterwards. We're looking forward to exciting discussions with you. Dr. Nils Kost Philipp Thiele Frederik M. Mader Dr. Hendrik Melior Hanno Härtlein Bernhard Remes Dr. Marc Hetzel Dr. Benedikt Linder Huma #ClinicalTrials
-
Alcedis - a HUMA company hat dies direkt geteilt
Update zu #Myoflame-19, der randomisierten klinischen Studie, die auf endotheliale Dysfunktion abzielt, um kardiale Symptome und Belastungstoleranz zu verbessern. Die Studie geht in die letzte Runde der Rekrutierung! Alle Zentren rekrutieren aktiv. Bitte bewerben Sie sich über die Website der Studie: https://lnkd.in/dDYAaD_b
-
Alcedis - a HUMA company hat dies direkt geteilt
Just arrived back home from #ESMO! It’s been 5 days of valuable learning about the latest advancements in cancer prevention, diagnosis, treatment, palliative care, and aftercare. We had the opportunity to meet with clinicians, researchers, and industry leaders from around the world, connecting with the brightest minds in oncology who are committed to making a real impact on patients' lives. I’m also excited to bring back insights and impressions to the Alcedis - a HUMA company team, reflecting on the studies we have been worked on so intensively over the years. It’s been incredible to see their efforts showcased by and shared with the ESMO community: #CARE1: Viktor Grünwald, #C-PATROL: Jalid Sehouli, #COMBI-EU: Peter Mohr, #DETECT IVa: Tanja Fehm, #DETECT V: @Wolfgang Janni, #ImmunoCobiVem: Dirk Schadendorf Alexandra Kubara, Andreas Jauslin, Dr. Barbara Stollfuss, Dr. Benedikt Linder, Farnaz Behroozi, Ph.D. , Prof. Dr. Felix Hilpert, Gregoire Guillet, Hamid Mahmoudpour, Prof. Dr. med. Jessica Hassel, Lars Muehlenhoff, Weichenthal Michael, Mila Schöne, Dr Mert Aral, Mischo Kursar, Myrto Boukovala, Ralf Gutzmer, Teresa Amaral
-
You want to elevate your understanding of skin cancer? 𝗧𝗵𝗲 𝟯𝟰𝘁𝗵 𝗚𝗲𝗿𝗺𝗮𝗻 #𝗦𝗸𝗶𝗻𝗖𝗮𝗻𝗰𝗲𝗿 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀 in #Würzburg provides a unique opportunity to do so. The renowned congress offers a broad spectrum of specialist contributions, from basic experimental research to current developments in clinical dermato-oncology, in particular the newest treatment options, and provides a comprehensive overview of current skin cancer research. Skin cancer remains the most common cancer worldwide and the rising incidence rates pose major challenges for medicine, nursing and healthcare systems. The conference will focus on the latest findings on #melanoma, the presentation and discussion of new therapeutic approaches, particularly in the field of immunotherapies (including cellular and bispecific agents), and improving the management of side effects of drug-based anti-cancer therapies. We look forward to improve our understanding of malignant skin diseases and to discover new perspectives in skin cancer research and patient engagement in clinical trials. See you there! Hanno Härtlein Katharina Bakhaus Janina Fox Deutsche Krebsgesellschaft e. V. (DKG) #ADO2024 #ClinicalTrials
-
You don't want to miss our #webinar 𝗼𝗻 𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿 𝟮𝟱, 𝟮𝟬𝟮𝟰! Our expert speakers will guide you through the nuances of leveraging #RWE, sharing insights on its role in the adoption of new treatments and its critical impact in the #InspeCKD study, which analyzed approximately 450,000 anonymized patient records from 1,250 general practices in Germany. We will discuss the tangible benefits of RWE, moving beyond theory to real-world application, and address the technical integration challenges encountered. Our speakers: Dr. Nils Kost - Director Evidence at AstraZeneca Philipp Thiele - General Manager of CompuGroup Medical SE & Co. KGaA Frederik M. Mader - Specialist in general medicine and Professor at IU International University Dr. Hendrik Melior - Project Manager Clinical Operations at Alcedis Click the link below to sign up for our webinar! ➡️ https://lnkd.in/efWUQiAw #ClinicalTrials #DrugDevelopment
-
Here's why you should join us at this year's #ESMO24 in the beautiful city of #Barcelona 👇 As one of the leading platforms for experts in oncology and stakeholders from around the world, the ESMO Congress offers educational and scientific insights into the latest breakthroughs in basic science, translational and clinical cancer research. We are focused on understanding the clinical perspective of the scientific advances in cancer biology, diagnostics, and new treatments and are looking forward to multidisciplinary discussions with professionals in the field. Particularly significant for us as a CRO is the growing role of real-world data in clinical research to streamline our processes and shape the future of precision medicine. Contact our attending experts to discuss how these advancements are influencing cancer research and clinical trials. ESMO - European Society for Medical Oncology Hanno Härtlein Dr Mert Aral Dr. Benedikt Linder and Mila Isabella Schöne #RWE #Oncology #ClinicalTrials
-
Wir suchen dich als Teil unseres Teams! 🚀 Als 𝗣𝗿𝗼𝗷𝗲𝗸𝘁𝗺𝗮𝗻𝗮𝗴𝗲𝗿 𝗸𝗹𝗶𝗻𝗶𝘀𝗰𝗵𝗲 𝗦𝘁𝘂𝗱𝗶𝗲𝗻 (𝗦𝗰𝗵𝘄𝗲𝗿𝗽𝘂𝗻𝗸𝘁 𝗔𝗧𝗠𝗣) / 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗣𝗿𝗼𝗷𝗲𝗰𝘁 𝗠𝗮𝗻𝗮𝗴𝗲𝗿 (𝗺/𝘄/𝗱) betreust du eigenverantwortlich klinische Arzneimittelprüfungen und baust den Studienbereich rund um ATMPs stetig weiter aus. 💼 Du übernimmst klassische Projektmanagement-Tätigkeiten und koordinierst professionell und engagiert multizentrische und (inter-)nationale Studien von namhaften Kunden mit hochinteressanten klinischen Indikationen. ➡️https://lnkd.in/eYm8VP3X ___________________________________________ Wir suchen zum nächstmöglichen Zeitpunkt einen 𝗦𝗼𝗳𝘁𝘄𝗮𝗿𝗲𝗲𝗻𝘁𝘄𝗶𝗰𝗸𝗹𝗲𝗿 (𝗺/𝘄/𝗱). 🖥️ Du bist erfahrener Code-Ninja? Besitzt gute Kenntnisse in OOP und hast ein Gespür für Design Patterns? Bei uns leistest du mit der Entwicklung von Software (Backend und/oder Frontend) einen bedeutsamen Beitrag zum medizinischen Fortschritt. Du führst technisch und inhaltlich anspruchsvolle Weiter- & Neuentwicklung von Softwareanwendungen durch und arbeitest mit interdisziplinären (Scrum-)Teams in internationalen Projekten zusammen. ➡️ https://lnkd.in/etN6kFdT Wir haben Dein Interesse geweckt? Dann bewirb dich ganz unkompliziert bei uns! #wehire #Jobs #ClinicalTrials
-
𝗝𝗼𝗶𝗻 𝗼𝘂𝗿 𝘂𝗽𝗰𝗼𝗺𝗶𝗻𝗴 #𝗪𝗲𝗯𝗶𝗻𝗮𝗿 to learn how Real-World Evidence is transforming drug development and accelerating improvements in patient care. Our speakers Dr. Nils Kost, Director Evidence at AstraZeneca, Philipp Thiele, General Manager of CompuGroup Medical SE & Co. KGaA, and Frederik M. Mader, specialist in general medicine and professor at IU International University, discuss together with Dr. Hendrik Melior, Project Manager Clinical Operations at Alcedis, the transformative role of RWE in drug development and its role in the adoption of new treatments. Practical insights and valuable lessons from the #InspeCKD study will be presented, which used approximately 450,000 anonymized data sets from 1,250 primary care practices to examine the status quo of #CKD in primary care in Germany. Sign up now for our webinar at the link below! ➡️ https://lnkd.in/eCjnSb4y #ClinicalTrials #MedicalResearch
Dieser Inhalt ist hier nicht verfügbar.
Mit der LinkedIn App können Sie auf diese und weitere Inhalte zugreifen.